Catalyst Biosciences (CBIO) Earns Coverage Optimism Rating of 0.16

News headlines about Catalyst Biosciences (NASDAQ:CBIO) have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Catalyst Biosciences earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.7866075234088 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Catalyst Biosciences stock traded down $0.09 during mid-day trading on Friday, hitting $10.06. 162,522 shares of the company were exchanged, compared to its average volume of 841,306. The company has a market capitalization of $121.22 million, a price-to-earnings ratio of -1.35 and a beta of 2.15. Catalyst Biosciences has a 12-month low of $3.11 and a 12-month high of $37.00.

Catalyst Biosciences (NASDAQ:CBIO) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.08. Catalyst Biosciences had a negative return on equity of 27.51% and a negative net margin of 2,983.40%. research analysts anticipate that Catalyst Biosciences will post -2.51 earnings per share for the current fiscal year.

A number of research firms have recently commented on CBIO. BidaskClub upgraded Catalyst Biosciences from a “hold” rating to a “buy” rating in a report on Saturday, April 21st. Zacks Investment Research raised Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research note on Wednesday, April 25th. ValuEngine raised Catalyst Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Finally, B. Riley set a $44.00 price objective on Catalyst Biosciences and gave the company a “buy” rating in a research note on Monday, May 14th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. Catalyst Biosciences has a consensus rating of “Hold” and a consensus target price of $19.50.

About Catalyst Biosciences

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.

Recommended Story: Should I follow buy, hold and sell recommendations?

Insider Buying and Selling by Quarter for Catalyst Biosciences (NASDAQ:CBIO)

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply